Evidence map›Paper›PMID 29236146›Full record

ReviewHerz2018

[Atherothrombosis : Novel therapeutic strategies].

O Soehnlein

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herz, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

O SoehnleinInstitute for Cardiovascular Prevention, Ludwig Maximilians University Munich, Pettenkoferstr. 9, 80336, München, Deutschland. oliver.soehnlein@gmail.com.
Ludwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite intensive scientific research over the past decades, atherosclerosis and atherothrombosis are the leading cause of mortality worldwide. During the recent past it has become clear that atherosclerosis is not merely a lipid-driven disease but a multifactorial process involving chronic inflammation of large arteries. This review article briefly outlines the mechanistic nature of atherosclerosis, presents a synopsis of the current state of the art treatment strategies and finally outlines several therapeutic options, which are in clinical and experimental testing.

Indexed as

AnimalsAnticoagulantsAspirinCarrier ProteinsClinical Trials as TopicHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasInflammationMiceOligonucleotides, AntisensePCSK9 InhibitorsPhospholipase A2 InhibitorsPlaque, AtheroscleroticPlatelet ActivationPlatelet AggregationAnticoagulantsAspirinCarrier ProteinsHydroxymethylglutaryl-CoA Reductase Inhibitorsmicrosomal triglyceride transfer proteinOligonucleotides, AntisensePCSK9 InhibitorsPCSK9 protein, humanPhospholipase A2 InhibitorsProprotein Convertase 9AtherosclerosisCardiovascular diseasesHyperlipidemiaInflammationPlatelet inhibition

Identifiers

PMID29236146
OpenAlexW2773662217

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.